Table 2 Hemodynamic parameters during the study period in patients with (group B) and without (group A) altered tissue perfusion
Parameter | T0 | T1 | T3 | T6 |
|---|---|---|---|---|
MAP (mmHg) | ||||
Group A | 78 (76–86) | 76 (72–86) | 72 (70–83) | 78 (75–82) |
Group B | 76 (74–90) | 73 (68–79) | 74 (72–86) | 75 (72–87) |
CI (L/min/m2) (n = 27) | ||||
Group A | 3.1 (2.9–3.2) | 3.2 (3.0–3.3) | 3.1 (2.9–3.5) | 3.2 (2.7–3.6) |
Group B | 3.0 (2.7–4.0) | 2.9 (2.7–4.1) | 3.0 (2.7–4.0) | 3.1 (2.9–3.8) |
Norepinephrine dose (mcg/kg/min) (n = 34) | ||||
Group A | 0.2 (0.2–0.5) | 0.2 (0.2–0.4) | 0.2 (0.1–0.3) | 0.2 (0.2–0.3) |
Group B | 0.2 (0.1–0.6) | 0.2 (0.1–0.7) | 0.3 (0.1–0.6) | 0.4 (0.3–0.8)#* |
Lactate concentration (mmol/l) | ||||
Group A | 1.5 (1.2–2.1) | 1.5 (1.2–2.3) | 1.5 (1.3–2.0) | 1.4 (1.3–1.6) |
Group B | 1.4 (1.2–2.1) | 1.5 (1.3–2.0) | 1.7 (1.5–2.1) | 2.2 (1.8–2.7)#* |
ScvO2 (%) | ||||
Group A | 71 (69–72) | 70 (69–74) | 71 (68–72) | 70 (68–71) |
Group B | 70 (68–71) | 71 (69–73) | 70 (68–74) | 69 (67–71) |
PPI | ||||
Group A | 1.7 (1.4–2.1) | 1.6 (1.2–1.9) | 1.9 (1.5–2.2) | 2.1 (1.3–2.2) |
Group B | 2.1 (0.8–2.3) | 1.6 (0.9–2.1) | 1.8 (1.4–2.2) | 1.5 (1.2–2.1) |